One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Michael Wang(St. Joseph Health System), Patrick M. Reagan(University of Rochester), Frederick L. Locke(Moffitt Cancer Center), Ioana Kloos, Roch Houot(Inserm), Nöel Milpied(Hôpital Cardiologique du Haut-Lévêque), Marie José Kersten(Hovon), Caron A. Jacobson(Dana-Farber Cancer Institute), Amer Beitinjaneh(University of Miami), John M. Pagel(University of Washington), John M. Timmerman(Sheba Medical Center), Samantha Jaglowski(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), David B. Miklos(Stanford University), André Goy(Hackensack University Medical Center), Javier Muñoz(The University of Texas MD Anderson Cancer Center), Max S. Topp(Universitätsklinikum Würzburg), Lianqing Zheng(Florida State University), Houston Holmes(Texas Oncology), Peter A. McSweeney(Mesoblast (United States)), Swaminathan Murugappan(Amgen (United States)), Weimin Peng(The University of Texas MD Anderson Cancer Center), Henry C. Fung(Fox Chase Cancer Center), Ian W. Flinn(Tennessee Oncology), John M. Rossi(Amgen (United States)), Brian T. Hill(Cleveland Clinic)
Cited by 14
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k